The antidepressant mianserin has been shown to extend the lifespan of Caenorhabditis elegans (C. SAR131675 mw elegans), a well-established model organism used in aging research. The extension of lifespan in C. elegans was shown to be dependent on increased expression of the scaffolding protein (ANK3/unc-44). In contrast, antidepressant use in humans is associated with an increased risk of death. The C. elegans in the laboratory are fed Escherichia coli (E. coli), a diet high in protein and low in carbohydrate, whereas a typical human diet is high in carbohydrates. We hypothesized that dietary carbohydrates might mitigate the lifespan-extension effect of mianserin.
To investigate the effect of glucose added to the diet of C. elegans on the lifespan-extension effect of mianserin.
Wild-type Bristol N2 and ANK3/unc-44 inactivating mutants were cultured on agar plates containing nematode growth medium and fed E. coli. Treatment groups included (C) control, (M50) 50 μM mianserin, (G) 73 mM glucose, and (M50G) 50 μM mianserin and 73 mM glucose. Lifespan was determined by monitoring the worms until they died. Statistical analysis was performed using the Kaplan-Meier version of the log-rank test.
Mianserin treatment resulted in a 12% increase in lifespan (P<0.05) of wild-type Bristol N2 worms but reduced lifespan by 6% in ANK3/unc-44 mutants, consistent with previous research. The addition of glucose to the diet reduced the lifespan of both strains of worms and abolished the lifespan-extension by mianserin.
The addition of glucose to the diet of C. elegans abolishes the lifespan-extension effects of mianserin.
The addition of glucose to the diet of C. elegans abolishes the lifespan-extension effects of mianserin.
Nimotuzumab is a humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody, nowadays used for tumour immunochemotherapy. This study aimed to label the conjugate DOTA-nimotuzumab with yttrium-90, in order to provide a β- emitting radioimmunoconjugate (90Y-DOTA-nimotuzumab) potentially useful to assess the feasibility of a new radio-guided surgery approach.
The synthesis of 90Y-DOTA-nimotuzumab was performed in two days. Nimotuzumab was conjugated with a 50 fold excess of DOTA and then labelled with 90Y3+. The 90Y-DOTA-nimotuzumab preparation was optimized considering several parameters such as pH, temperature and reaction volume. Moreover, the 90Y-DOTA-nimotuzumab stability was evaluated in human plasma.
The radioimmunoconjugate 90Y-DOTA-nimotuzumab was obtained with a radiochemical purity greater than 96%, and showed a good stability at 20°C as well as at 37°C in human plasma.
The optimized conditions for a mild and easy preparation of 90Y-DOTA-nimotuzumab joined to a promising stability under physiological conditions suggest to propose this radioimmunoconjugate as a potential diagnostic radiopharmaceutical for β- radio-guided surgery.
The optimized conditions for a mild and easy preparation of 90Y-DOTA-nimotuzumab joined to a promising stability under physiological conditions suggest to propose this radioimmunoconjugate as a potential diagnostic radiopharmaceutical for β- radio-guided surgery.
There is no single-component excipient that fulfils all the requisite performance to allow an active pharmaceutical ingredient to be formulated into a specific dosage form. Co-processing is a novel concept that incorporates combination of two or more excipients which is advantageous and cannot be achieved using a physical admixture.
This review provides an overview of co-processed excipients, recent patents granted and filed in this field and the commercial patented technology platforms based on these excipients.
Various online patent databases were used for collecting the information on recent patents and patented co processed excipient technologies. The recent patents such as single-step co-processing by dry coating, novel co-processed excipients for oily drugs and novel silica-coated compositions have been discussed.
Co-processed excipients are evolving as a current and future trend of excipient technology in pharmaceutical manufacturing which is evident by increasing number of patents based on these excipients. Among various techniques, the maximum number of patents is based on spray drying technique.
In this work, the authors have focussed on recent patents and commercial technologies on co-processed excipient. A better understanding of this will help researchers and pharmaceutical industries to select the appropriate platform, or to develop new innovative co-processed excipients with improved tableting characteristics.
In this work, the authors have focussed on recent patents and commercial technologies on co-processed excipient. A better understanding of this will help researchers and pharmaceutical industries to select the appropriate platform, or to develop new innovative co-processed excipients with improved tableting characteristics.
To test the effectiveness of marketed polyherbal formulations on lipopolysaccharide induced inflammatory conditions in macrophages.
Usage of herbal compounds among patients suffered by arthritis and cancer is increasing every year. Many anti-inflammatory herbal products available in the market should be screened thoroughly for their possible mechanism of action.
Joint Pain Spl (JPS) is a polyherbal dietary food supplement composed of 13 herbal plants and Rumalaya Forte (RF) is a polyherbal formulation comprising of 6 herbal plants were tested for its cytotoxicity, as well as antioxidant and anti-inflammatory activity in LPS treated IC-21 peritoneal macrophages.
Commercially available JPS and RF powder was used to prepare the extract. The aqueous and methanol extracts were quantified for the presence of phenolic and flavonoid compound and confirmed with HPLC. In vitro DPPH free scavenging activity was performed. Cytotoxicity was tested by MTT assay. Anti-inflammatory activity was tested using lipopolysy by modulating free radical generation in IC-21 macrophages. Thus the presence of the phenolic and flavonoid compounds may contribute to the antioxidant activity.SAR131675 mw
Top comments (0)